Pathology Visions 2025
Aug. 13, 2025—Pathology Visions 2025 (PathVisions25) is the premier annual meeting of the Digital Pathology Association (DPA), bringing together over 850 global health care professionals and industry innovators.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
FDA clears assay to detect CTX-M enzymes
Aug. 12, 2025—Hardy Diagnostics announced FDA clearance of the NG-Test CTX-M Multi, an in vitro diagnostic immunoassay for the qualitative detection of CTX-M enzymes (groups 1, 2, 8, 9, and 25) from pure colonies of Enterobacterales suspected of extended-spectrum beta-lactamase production.
Thermo Fisher nabs FDA approval for NSCLC CDx
Aug. 11, 2025—Thermo Fisher Scientific has received FDA approval for its Oncomine Dx Target test as a companion diagnostic to identify patients who may be candidates for zongertinib (Hernexeos, Boehringer Ingelheim), a tyrosine kinase inhibitor.
Evident to acquire Pramana
Aug. 8, 2025—Evident announced a definitive agreement to acquire Pramana.
New CAP PT/EQA program for POC troponin I
Aug. 5, 2025—The CAP announced in June a new proficiency testing/external quality assessment program for point-of-care high-sensitivity troponin I.
Roche gets clearance for Cobas Respiratory 4-flex
Aug. 4, 2025—Roche announced FDA 510(k) clearance for its Cobas Respiratory 4-flex assay.
Clinisys acquires Orchard Software
July 30, 2025—Clinisys has acquired Orchard Software from investment firm Francisco Partners, which bought Orchard in 2019.
Ascentry debuts at ADLM 2025
July 29, 2025—Ascentry, formerly BYG4lab, officially debuted at the Association for Diagnostics and Laboratory Medicine annual meeting (Chicago, July 27–31).
Roche receives CE mark for Elecsys pTau181
July 28, 2025—Roche has received the CE mark for its Elecsys pTau181 test to measure phosphorylated tau 181 protein, an indicator of amyloid pathology.
MeMed completes development of MeMed BV Flex
July 25, 2025—MeMed has completed its multiyear development of MeMed BV Flex, a next-generation test designed to expand the reach of MeMed BV into decentralized, CLIA-waived settings